As a reversible pan-class PI3K inhibitor, LY294002 has been demonstrated to alleviate LTP impairment and TNF-α and IL-6 reduction while improving fear conditioning in preclinical models of sepsis-associated encephalopathy and cerebral hypoperfusion. This evidence concerns the gene PIK3CD and Sepsis.